Should clinicians reconsider standard therapy for gout?

Gout occurs when urate crystals accumulate in the joints, and xanthine oxidase inhibitors such as febuxostat are a mainstay of therapy to help reduce blood urate levels in affected patients. A recent clinical trial published in Arthritis & Rheumatology has found that low doses of a less commonly used drug called benzbromarone may be a better option, however.

source https://medicalxpress.com/news/2022-07-clinicians-reconsider-standard-therapy-gout.html